상세 보기
뇌전증약을 복용 중인 뇌전증 환자에서 코로나바이러스감염증-19 치료제를 사용할 때 고려사항
- 변정익;
- 선우준상;
- 강경욱;
- 김근태;
- 김대영;
- ... 문혜진;
- 외 8명
초록
Several medications are approved to treat coronavirus disease 2019 (COVID-19) in Korea including nirmatrelvir/ritonavir, remdesivir, and regdanvimab. There is potential drug-drug interaction between antiepileptic drugs (AEDs) and the medications used to treat COVID-19. Several AEDs such as phenytoin, carbamazepine, phenobarbital, and primidone are strong cytochrome P450 inducers and can inhibit the drugs used for COVID-19. Particularly, these drugs are contraindicated with nirmatrelvir/ritonavir (Paxlovid® ). There is a weaker drug-drug interaction between the AEDs and remdesivir. No significant interaction has been reported between the AEDs and molnupiravir. Pharmacokinetic interactions of the AEDs are important in effective management of COVID-19 in patients with epilepsy
키워드
- 제목
- 뇌전증약을 복용 중인 뇌전증 환자에서 코로나바이러스감염증-19 치료제를 사용할 때 고려사항
- 제목 (타언어)
- Consideration for Coronavirus Disease 2019 Drug Treatment in Patients with Epilepsy on Antiepileptic Drugs
- 저자
- 변정익; 선우준상; 강경욱; 김근태; 김대영; 김동욱; 김세윤; 김세희; 김우준; 문혜진; 박혜리; 서종근; 황경진; 서대원
- 발행일
- 2022-05
- 저널명
- 대한신경과학회지
- 권
- 40
- 호
- 2
- 페이지
- 121 ~ 126